Opinion|Videos|July 16, 2024
Economic Impacts and Pricing Strategies Surrounding Biosimilars
The panel discusses the economic impact biosimilars have across different patient types.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What economic impacts do biosimilars have in different delivery channels (inpatient, self-administered outpatient, outpatient infusion)?
- How do pricing strategies for biosimilars, such as the high and low list prices of adalimumab biosimilars, affect their market penetration and adoption?
- How do biosimilar pricing strategies affect patient access and affordability?
- Are there more effective pricing models that could be adopted?
- Are there certain customer subtypes that will want a rebate drive model vs. those want a rebate driven model vs. a WAC driven model?
Advertisement
Related to this article
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Advertisement
Advertisement
Trending on AJMC
1
Preparing Practices for the Next Era of Hepatitis B Care
2
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
3
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
4
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
5